NCT00189709

Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia

A Single Center, Open, Parallel, Comparative, Randomized Study of Micafungin (FK463) vs Fluconazole (Diflucan) in the Treatment of Invasive Candidiasis and Candidaemia (Protocol No: MCFGCAN-0301F-TW)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia

Detailed description

Micafungin (a new class of antifungal drugs) is compared to fluconazole (current standard treatment) in the treatment of patients with serious fungal infections (invasive candidiasis and candidemia) to determine its efficacy and safety. Patients, both male and female, aged over 16 and with confirmed disease by the doctor could be recruited and evaluated.

Conditions

• Invasive Candidiasis
• Candidemia

Interventions

Type	Name	Description
DRUG	Micafungin	IV
DRUG	fluconazole	IV

Timeline

• Start date: 2004-08-01
• Primary completion: 2006-07-01
• Completion: 2006-07-01
• First posted: 2005-09-19
• Last updated: 2008-01-02

Locations

1 site across 1 country: Taiwan